Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-03-01 4:30 pm Unchanged | 13D | NEWAMSTERDAM PHARMA CO NV SHS NAMS | BCLS II Investco LP | 5,376,356 6% | 0 (Unchanged) | View |
| 2024-02-21 11:11 am Unchanged | 13D | NEWAMSTERDAM PHARMA CO NV SHS NAMS | Frazier Life Sciences X L.P. | 12,632,038 14.2% | 0 (Unchanged) | View |
| 2024-02-14 5:01 pm Sale | 13G | NEWAMSTERDAM PHARMA CO NV SHS NAMS | RA CAPITAL MANAGEMENT L.P. | 8,197,333 9.9% | -1,136,000 (-12.17%) | View |
| 2024-02-14 10:12 am Purchase | 13G | NEWAMSTERDAM PHARMA CO NV SHS NAMS | VIKING GLOBAL INVESTORS LP | 8,024,565 9.7% | 1,500,000 (+22.99%) | View |
| 2023-09-19 9:30 pm Purchase | 13G | NEWAMSTERDAM PHARMA CO NV SHS NAMS | Morningside Venture Investments Ltd | 4,060,923 4.93% | 4,060,923 (New Position) | View |
| 2023-08-15 4:02 pm Purchase | 13D | NEWAMSTERDAM PHARMA CO NV SHS NAMS | Frazier Life Sciences X L.P. | 12,632,038 15.3% | 1,485,807 (+13.33%) | View |
| 2023-08-01 4:30 pm Purchase | 13G | NEWAMSTERDAM PHARMA CO NV SHS NAMS | RA CAPITAL MANAGEMENT L.P. | 9,333,333 11.3% | 5,000,000 (+115.38%) | View |
| 2023-07-07 5:06 pm Purchase | 13D | NEWAMSTERDAM PHARMA CO NV SHS NAMS | Forbion Capital Fund IV Cooperatief U.A. | 11,831,461 14.5% | 3,589,061 (+43.54%) | View |
| 2023-07-07 5:00 pm Purchase | 13D | NEWAMSTERDAM PHARMA CO NV SHS NAMS | Forbion Capital Fund IV Cooperatief U.A. | 8,242,400 10.1% | 8,242,400 (New Position) | View |
| 2023-06-20 4:30 pm Purchase | 13G | NEWAMSTERDAM PHARMA CO NV SHS NAMS | VIKING GLOBAL INVESTORS LP | 6,524,565 7.98% | 6,524,565 (New Position) | View |
| 2023-06-13 5:04 pm Purchase | 13D | NEWAMSTERDAM PHARMA CO NV SHS NAMS | BCLS II Investco LP | 5,376,356 6.6% | 1,376,356 (+34.41%) | View |
| 2023-06-09 3:47 pm Purchase | 13D | NEWAMSTERDAM PHARMA CO NV SHS NAMS | Frazier Life Sciences X L.P. | 11,146,231 13.5% | 11,146,231 (New Position) | View |
| 2022-12-02 4:30 pm Purchase | 13G | NEWAMSTERDAM PHARMA CO NV SHS NAMS | RA CAPITAL MANAGEMENT L.P. | 4,333,333 5.29% | 4,333,333 (New Position) | View |
| 2022-12-02 4:24 pm Purchase | 13D | NEWAMSTERDAM PHARMA CO NV SHS NAMS | BCLS II Investco LP | 4,000,000 4.9% | 4,000,000 (New Position) | View |
| 2022-12-02 4:05 pm Purchase | 13G | FRAZIER LIFESCIENCES ACQ CORP FLAC | Morningside Venture Investments Ltd | 5,065,846 6.21% | 5,065,846 (New Position) | View |
| 2022-12-02 06:01 am Purchase | 13G | NEWAMSTERDAM PHARMA CO NV SHS NAMS | AMGEN INC AMGN | 4,910,000 6% | 4,910,000 (New Position) | View |
| 2022-12-01 5:33 pm Purchase | 13D | NEWAMSTERDAM PHARMA CO NV SHS NAMS | Frazier Lifesciences Sponsor LLC | 9,801,333 12% | 9,801,333 (New Position) | View |